Clover Health Investments, Corp. (CLOV)
| Market Cap | 2.48B +59.7% |
| Revenue (ttm) | 2.48B +54.0% |
| Net Income | -18.36M |
| EPS | -0.04 |
| Shares Out | 531.16M |
| PE Ratio | n/a |
| Forward PE | 64.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,516,994 |
| Open | 4.610 |
| Previous Close | 4.540 |
| Day's Range | 4.520 - 4.690 |
| 52-Week Range | 1.580 - 5.590 |
| Beta | 2.48 |
| Analysts | Buy |
| Price Target | 5.38 (+15.2%) |
| Est. Earnings | Nov 3, 2026 |
About CLOV
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Financial Performance
In 2025, Clover Health Investments's revenue was $1.92 billion, an increase of 40.33% compared to the previous year's $1.37 billion. Losses were -$85.55 million, 98.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLOV stock is "Buy." The 12-month stock price target is $5.38, which is an increase of 15.20% from the latest price.
News
Clover Health Investments Transcript: 2026 Jefferies Healthcare Services and Technology Conference
A differentiated technology-driven approach, full-risk model, and focus on PPO plans underpin strong member retention and growth. Industry-wide pricing discipline and benefit stability are driving selective disruption, while ongoing AI and R&D investments support margin recovery and profitability.
Clover Health initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target The firm views Clover as an investment in the expanding Medicare Advantage market at…
Clover Health initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following inv...
Clover Health Investments Transcript: Canaccord Genuity's 46th Annual Growth Conference
The presentation highlighted a differentiated, technology-driven approach to Medicare Advantage, emphasizing proactive care, rapid membership growth, and strong retention. Cohort maturation and in-home care are driving profitability, with expectations for continued expansion and industry-leading outcomes.
Clover Health Investments Slides: Investor presentation
Clover Health Investments has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Clover Health price target raised to $5 from $4.75 at UBS
UBS analyst Jonathan Yong raised the firm’s price target on Clover Health (CLOV) to $5 from $4.75 and keeps a Neutral rating on the shares.
Clover Health Investments Earnings Call Transcript: Q2 2026
Medicare Advantage membership grew 48% year-over-year, driving a 56% revenue increase and strong profitability gains. Full-year guidance was raised across all metrics, with continued operating leverage and a favorable star rating supporting future growth.
Clover Health Investments Earnings release: Q2 2026
Clover Health Investments released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Clover Health Investments Slides: Q2 2026
Clover Health Investments has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Clover Health Investments Quarterly report: Q2 2026
Clover Health Investments has published its Q2 2026 quarterly earnings report on August 5, 2026.
Clover Health Reports Second Quarter 2026 Results
Business Highlights: Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth Improved Full Year 2026 guidance across all metrics In...
Clover Health to Participate in Upcoming Canaccord Genuity 46th Annual Growth Conference
WILMINGTON, Del., July 22, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Offic...
Clover Health price target raised to $5.50 from $4.20 at Canaccord
Canaccord raised the firm’s price target on Clover Health (CLOV) to $5.50 from $4.20 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Clover Health says employee accounts accessed in cyber incident
Clover Health Investments said in a regulatory filing on Friday that it detected unusual login activity on some of its information systems on July 4 and later found a hacker had gained access to thr...
Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026
WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial res...
Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or “Clover Health”), a...
Clover Health price target raised to $4.75 from $2.75 at UBS
UBS analyst Jonathan Yong raised the firm’s price target on Clover Health (CLOV) to $4.75 from $2.75 and keeps a Neutral rating on the shares.
Clover Health Investments Transcript: AGM 2026
The meeting confirmed the election of directors, approval of executive compensation, and auditor ratification. Financial results showed strong membership growth and profitability, with ongoing investment in AI-driven care and expansion of the care model. No stockholder questions were raised on voting matters.
Clover Health price target raised to $4.20 from $3.20 at Canaccord
Canaccord analyst Richard Close raised the firm’s price target on Clover Health (CLOV) to $4.20 from $3.20 and keeps a Buy rating on the shares. The firm said its 2026…
Clover Health Investments Earnings Call Transcript: Q1 2026
Q1 2026 saw 51% membership growth, $27M GAAP net income, and 62% revenue growth year-over-year. Gross profit rose 47%, with strong retention, clinical engagement, and scale efficiencies supporting a positive outlook for 2026.
Clover Health Investments Earnings release: Q1 2026
Clover Health Investments released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.